KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).

Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, Elke Platz, Martina Brueckmann, Ania M Jastreboff, Samina Ajaz Hussain, Sue D Pedersen, Luiza Borowska, Anna Unseld, Isabel M Kloer, Lee M Kaplan, SYNCHRONIZE‐1 and ‐2 trial committees and investigators

Obesity (Silver Spring) 33(1) 67-77

PMID39495965
PMCIDPMC11664303
DOI10.1002/oby.24184
发表日期2024-11-04
摘要

摘要

OBJECTIVE: The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE-1 and -2). METHODS: In these ongoing double-blind trials, participants were randomized to once-weekly subcutaneous injections of survodutide or placebo added to lifestyle modification. Survodutide doses are uptitrated to 3.6 or 6.0 mg, and dose flexibility is permitted. Participants (n = 726) in SYNCHRONIZE-1 (NCT06066515) have a baseline BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication but without T2D; participants (n = 755) in SYNCHRONIZE-2 (NCT06066528) have a baseline BMI ≥ 27 kg/m2 and T2D. The primary endpoints are percentage change in body weight and proportion of participants achieving ≥5% body weight reduction from baseline to week 76. Secondary endpoints include change in systolic blood pressure and measures of glycemia. A SYNCHRONIZE-1 substudy is evaluating changes in body composition and liver fat content using magnetic resonance imaging. CONCLUSIONS: These trials are designed to provide robust evaluation of the efficacy, safety, and tolerability of survodutide for the treatment of obesity in the presence or absence of T2D.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。